Malaria and the traveller by Tonna, Antonella & Tonna, Ivan
22          Journal of the Malta College of Pharmacy Practice Issue 10 Summer 2005
Malaria
and the traveller
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Malaria has reached epidemic proportions. About 40% of the world’s
population live in malarious areas. It is estimated that 400 million
people are infected by malaria each year and of these, 1-3 million die,
mostly children under five years of age.1  In the year 2000, malaria
was estimated to be the cause for the loss of nearly 45 million
Disability Adjusted Life Years (DALYs) and this accounts for 13% of all
DALYs associated with infectious diseases.2 Malaria has gained
importance in Western Europe, including Malta, mainly due to the
increasing tourism to malaria endemic countries. There have been 21
reported cases of malaria in Malta between the years 2000-2003.3
Life cycle of malaria parasite
There are two phases in the malaria life
cycle (Figure 1); one occurring in the
intermediate host (humans, birds, reptiles)
and the other occurring in the definitive
host (mosquitoes). This review will
concentrate mainly on the intermediate
host.
When an infected anophele mosquito
bites a human being, sporozoites are
inoculated into the subcutaneous tissue, or
rarely, into the bloodstream. These are
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then taken up by hepatocytes through a
receptor-mediated mechanism.4 Here, the
sporozoites develop into schizonts and
depending on the infecting plasmodium
species, will either divide into a large
number of merozoites or enter into a
dormant phase, hypnozoites, the latter
occurring with infection by Plasmodium
ovale and vivax. Once merozoites are
released into the circulation, they invade
erythrocytes and become ring-shaped
trophozoites.5 Trophozoites enlarge by
feeding on haemoglobin and the by-product
of digestion is released within the red blood
cell as insoluble haemozoin. When the
trophozoite has become mature, it forms a
schizont and starts to divide so that by the
end of the cycle, there would be between 8-
24 merozoites ready to emerge and infect
new red cells. This cycle is known as
erythrocytic schizogony. Eventually some of
the merozoites will differentiate into
immature gametocytes. These are important
for continuation of the life cycle within the
definitive host. Once immature gametocytes
are taken up by the mosquito during a blood
meal, they differentiate into macrogametes
and microgametes within the stomach. After
a process of exflagellation, the microgamete
releases 6-8 flagella, one of which goes on
to fertilise the macrogamete. Within 24
hours the resulting zygote develops into an
ookinete and this penetrates the midgut
wall to become an oocyst lying between the
midgut epithelium and basal lamina.6
Following a series of asexual divisions, a
number of sporozoites are formed. These are
then released from the oocyst and migrate
towards the salivary glands ready to be
transferred during the mosquito’s next blood
meal.
Classification and mode
of action of antimalarials
Antimalarials may be classified
depending upon the stage of the malaria
cycle they act upon. This in turn will
determine their use. (Figure 1, Table 1)
A. Tissue schizontocides – defined as
compounds acting on pre-erythrocytic forms
in the liver. This may in turn be divided
into:
Tissue schizontocides used for causal
prophylaxis. These agents prevent
development of the parasite within the liver.
Thus, merozoites are not released into the
bloodstream and both the asexual and
sexual stages of the lifecycle are prevented.
Example include pyrimethamine.7,8
Tissue schizontocides used to prevent
relapse. These kill the dormant hypnozoites
in the liver that are responsible for relapses
seen with P. vivax and P. ovale infections.
Example includes primaquine.7,8,9
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Table 1: Mode of action and use of antimalarials
Drug Class Classification Mode of action Use
Arylaminoalcohols Blood Precise mode of action is still not clear. • Treatment of acute disease –
Quinine schizontocides Believed to act by inhibiting the quinine is the drug of choice. Due to
Quinidine polymerisation of haemin into its increased cardiotoxicity, quinidine
Mefloquine haemozoin12 is used only if quinine is not available7
Halofantrine • Suppressive prophylaxis – mefloquine
is used in areas of chloroquine-resistant
malaria
4 – aminoquinolines Blood Precise mode of action still not clear. • Treatment of non-falciparum malaria -
and related compounds schizontocides Believed to act by inhibiting the should not be used in falciparum,
Chloroquine polymerisation of haemin into haemozoin. unknown infective species or mixed
Amodiaquine Also appears to affect cell growth by infection14
Mepacrine interfering with DNA12,13 • Suppressive prophylaxis – Chloroquine
Pyronaridine • Amodiaquine, Mepacrine and Pyronaridine
– use obsolete and not recommended7
Sulfones and Type I antifolate Compete for dihydropteroate synthase • Causal prophylaxis
sulfonamidesa inhibitors found only in the malaria parasite and • Treatment
Dapsone required in the pathway to synthesize DNA7,8
Sulfamethoxypyrazine
Sulfadoxine
Biguanides and Type II antifolate Inhibit dihydrofolate reductase used • Causal prophylaxis
diaminopyrimidines inhibitors by the malaria parasites to make folinic • Treatment of infections resistant to
Proguanil acid cofactors for synthesis of DNA. other blood schizontocides7
Chlorproguanil Prevent the completion of schizogony • Used in combination with quinine to
Pyrimethaminea leading to large abnormal looking ensure clinical cure in quinine-resistant
trophozites11 falciparum malaria7
• Pyrimethamine should only be used
in combination14
8 – aminoquinolines Hypnozoiticidal and  Converted to quinone active metabolites • Prevention of transmission of falciparum
Primaquine gametocytocidal in liver and are particularly active against • Antirelapse for vivax and ovale malaria
non-growing stages of the parasite7
Antibiotics Blood Inhibitors of parasitic ribosomal protein • Treatment: used in combination with
Doxycycline schizontocides synthesis. Azithromycin is under quinine in effecting cure7,14
Clindamycin investigation for antimalarial activity 7,12 • Doxycycline: a suppressive prophylactic
Fluoroquinolones for multiresistant falciparum malaria14
Peroxide antimalarials Blood Act on malaria parasite engaged in digesting • Acute uncomplicated falciparum including
Artemisinin (from the schizontocides haemoglobin in erythrocytes where they are parasites resistant to chloroquine and
Chinese medicinal thought to interfere with the conversion quinine14
plant  Artemisia annua) of haem to the nontoxic haemozin7,15
Hydroxynaphthoquinones Blood Atovaquone acts on the electron transport • Atovaquone (250mg) with proguanil
Atovaquone schizontocides chain in the malarial mitochondrion causing (100mg) combination (MalaroneTM)
collapse of the mitochondrial membrane indicated for prophylaxis and treatment
potential. Proguanil potentiates this16,17 particularly where drug-resistant
falciparum malaria exists16
a In most cases Type I antifolate drugs are combined with Type II antifolate drugs for synergistic action. Combinations include: dapsone with pyrimethamine (MaloprimTM,
DeltaprimTM), sulfamethoxyprazine with pyrimethamine (MetakelfinTM), sulfadoxine with pyrimethamine (FansidarTM)
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B. Blood schizontocides – these act
on the asexual erythrocytic part of the
malaria life cycle. They act in one of two
ways. Drugs, such as mefloquine and
quinine, concentrate in the parasite
lysosomes within the infected erthyrocytes,
thus interfering with the parasitic
digestion of haemoglobin. The breakdown
product, haemin, is toxic to the parasite
and is normally polymerised into non-toxic
haemozoin, an action inhibited by the
drugs. Sulfones and proguanil have
antifolate activity, thereby inhibiting
different stages of DNA production in the
parasite. 7,8,10,11
C. Gametocytocides – these include
primaquine and destroy the sexual forms of
the parasite in the blood, hence preventing
transmission to the mosquito.7,8,9
D. Sporontocides – these prevent
parasite transmission by preventing oocyte
formation within the mosquito stomach
wall. Sporozoite formation is therefore
inhibited and this prevents parasite
transmission to the human host.
Primaquine exhibits this mode of action.7,8
Use of antimalarial combinations
Multidrug resistance is the biggest
challenge hindering effective prophylaxis
and treatment and has made it necessary
to use antimalarial combinations.
Combination therapy has been defined by
the World Health Organization (WHO) as
“the synergistic or additive potential of two
or more drugs, to improve therapeutic
efficacy and also delay the development of
resistance to the individual components of
the combination”.18 Drugs used in
combination are usually blood
schizontocidal drugs that have different
modes of action on the parasite. Various
factors contribute towards making an ideal
combination. These include:  safety
(synergistic and additive adverse effects
may be a problem when drugs are used in
combination), acceptability to the patient
(side effect profile, product presentation,
co-formulation in a single formulation,
packaging ensuring stability in hotter
climates, simple dose schedules) and
potential to delay or prevent resistance
development.18,19 Limitations to use of
combination therapy include: cost (with
combinations costing up to 10 times that
of monotherapy), lack of evidence in
particular patient groups, such as
pregnancy and paediatrics and the choice
of drug combinations depending on the
resistance patterns.18
Malaria and the traveller
The UK Guidelines for travellers define
the aim of prophylaxis as ‘to prevent illness
and death in people who travel to areas
where malaria is transmitted.’20 The risk of
acquiring malaria can be reduced by
providing adequate and evidence-based
advice to travellers and appropriate
chemoprophylactic cover when needed. It
is very common for travellers preparing to
go abroad to present at community
pharmacies for insect bite repellents and
over-the-counter medications to take on
their journey abroad. To ensure successful
malaria prophylaxis, the pharmacist
requires a sound knowledge of four key
steps:  Awareness, Bites, Compliance and
Diagnosis.20
Awareness – knowing about
the risk of malaria
In choosing the most effective regimen
and ensuring that appropriate advice is
given, various factors affecting the risk of
malaria need to be considered for each
individual. These include:
• Places to be visited
Malaria is only present in particular areas
of the world and is endemic and easily
transmissible in areas lying between 64o
North and 32o South.21 Within this
region, risk of transmission may be
higher in one area compared to another;
for example, in parts of Tanzania, malaria
is holoendemic and transmission occurs
perennially while in Sudan, malaria is
mesoendemic and transmission is
seasonal.22 The difference lies in the
entomological inoculation rate, which is
the average number of infective bites per
unit time. This varies in different areas
and can range from less than 1 to more
than 1000 infected bites per year in
different parts of Africa.23
• Areas of drug resistance
The presence of chloroquine-resistant
falciparum malaria is increasing
worldwide with only small areas of the
world still having chloroquine-sensitive
Plasmodium falciparum; for example, the
Caribbean regions.20
• Duration of visit
The duration of stay in a malarious area
is important. It is known that the longer
one spends in a malarious region the
higher the risk of acquiring malaria.20 In
fact, with short visits to certain areas of
Africa, the use of chemoprophylaxis is
questionable since the risks of adverse
events with these medications may
outweigh the risks of acquiring the
disease.12 In such cases, expert advice
needs to be sought.
• Type of traveller and degree of
exposure
This includes pattern of activity at dusk/
dawn and mode of travel. Backpackers
and travellers working in rural areas are
at higher risk. Likewise those visiting
friends and relatives may be at a higher
risk due to the often misconceived idea
that since they frequently visit the
malarious areas they are immune to the
disease.12,20
Bites – learning how to prevent
or avoid mosquito bites
Travellers need to be advised on
precautions to prevent insect bites (Figure
2). Since insect repellents are the mainstay
of bite avoidance, the pharmacist should
have a sound knowledge to ensure effective
use. Repellents need to be applied
frequently since their duration of activity is
diminished by sweat on the skin, the
ambient and body temperatures, windy
conditions and activities such as
swimming.24,25 Travellers should therefore
be advised to reapply more frequently than
the time stated on the label if the effects
seem to be wearing off.24 Repellents are
also not suitable for overnight protection
and insecticide-impregnated mosquito nets
are therefore crucial unless an air-
conditioned room with sealed windows is
used.25 When a sunscreen is needed, this
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should be applied first and the repellent
applied over.24 Sunscreens may lose some of
their efficacy and therefore other
additional precautions should be taken.26,27
It is worth noting that research has
indicated that travellers are more likely to
comply with chemoprophylaxis rather than
use of repellents and consequently the
pharmacist needs to select a product that
is acceptable to the patient to maximise
concordance.24 DEET remains the ‘gold
standard’ and an independent trial
comparing this to other repellents showed
DEET to be the most effective.24
Unfortunately, DEET-containing products
are not always readily available due to
controversy about adverse effects. Due to
the length of time it has been on the
market, the largest amount of evidence is
available for DEET and analysis indicates a
remarkable safety profile.27,28 In fact,
guidelines formulated by expert panels still
recommend it as the first choice where
there is a risk of malaria.20 Patients should
be warned that DEET may damage plastic
objects and synthetic fabrics.25 Pharmacists
should also note that there is little or no
evidence to support the use of electronic
devices that claim to repel mosquitoes by
emitting an ultrasonic noise.20,24
Compliance with appropriate
chemoprophylaxis
It is crucial to refer to suitable updated
sources (examples of suitable sources are
listed at the end). One should keep in mind
that different drugs are available in
different countries and guidelines may
therefore vary leading to confusion. It is
recommended to start treatment one week
before to enable any adverse effects to be
detected beforehand and to ensure that the
blood level of the drug is within
therapeutic range prior to reaching the
malaria endemic region.12,14,20 Mefloquine is
an exception and current guidance
recommends starting the drug two and a
half weeks before travel ensuring that 3
doses are taken before travel and any
adverse effects noted.10,12,14,20 Atovaquone/
proguanil prophylaxis should be started 24
to 48 hours before departure.14,16 All
regimens should be taken regularly during
the travel period and for up to four weeks
(one week in the case of atovaquone/
proguanil) after return in case there is any
parasite emerging from the pre-erythrocytic
stage.12,14,16,20  Drugs may be taken after
meals with water to minimise adverse
effects. It is worth noting that the rate of
malaria contraction due to non-compliance
is probably as high as that due to malaria
resistance, and concordance with the
prescribed regimen needs to be reinforced
by the pharmacist.12 Travellers should be
advised to take enough tablets to cover
Figure 2: Care issues to consider when giving advice on bite avoidance20,24,25,28
Recommended?
DEET-based
compounds first
choice when risk of
malaria (largest
body of evidence)
Alternative?
All others are less
effective. Second
best is lemon
eucalyptus extract
Dose?
30-50% DEET. 20-
30% sustained
release especially
in children and
pregnant women
When to apply?
Early evening and
before retiring. Do
not apply at
bedtime and wash
off repellent before
going to bed
How is it applied?
Applied to exposed
skin or clothing.
Special care when
using on face and
avoid eyes and
mouth
Adverse events?
Skin reactions
(especially if left
overnight). Can
irritate eyes or
mucous membranes
Clothing?
Light coloured
clothes; long
sleeves/trousers;
socks; avoid
perfume and
after-shave lotion
Bed nets?
Take one especially
if sleeping outside
or in an unscreened
room. Buy nets
treated with
permethrin
Retreatment
of bed nets?
Retreat if your stay
is >6 months.
Retreatment kits
are readily
available.
Formulation?
Aerosol spray or
liquid. Second best
would be coils or
electronic mats
Where used?
Sprays to deter
insects from
entering room.
Liquid to treat bed
nets
Insect Repellents
Barrier Protection Insecticides
Recommended?
Permethrin-based
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the whole trip since it may be a problem to
obtain these in the visiting country.25 To
ensure the most effective and least toxic
chemoprophylactic for the individual
patient, a number of care issues need to be
considered (Figure 3) since numerous
factors may complicate the choice of
treatment. The incidence of adverse effects
is very difficult to predict and is sometimes
based on subjectivity. Though databases for
reporting adverse effects are available, it is
difficult to determine the exact incidence
Figure 3 : Care issues to consider when choosing appropriate antimalarial prophylaxis
Age of traveller Child’s weight is a better guide than
age to determine dose14
Doxycycline is contraindicated20
Breast-fed infants are not protected
by drug in their mother’s milk25
Readminister if child vomits within
one hour of administration29
Female
Child
<12 years of age
Gender Proguanil, chloroquine
safe in pregnancy20
Doxycycline, atovaquone/proguanil
contraindicated in pregnancy
and breastfeeding20
Patients taking mefloquine
should use contraception for
3 months after the last dose10, 20
Is patient likely
to get pregnant
whilst abroad?
Is patient on
concurrent medication?
Check for drug interactions (example,
proguanil interacts with warfarin)12
Is there a past medical history of
renal/hepatic, cardiac
arrhythmias, myasthenia gravis,
psychiatric disorders or psoriasis?
Ask for expert advice
Reduce dose of proguanil
in renal failure11
Care with use of mefloquine and
doxycycline in hepatic failure10,20
Chloroquine may cause
flare-up of psoriasis12,13
Mefloquine contraindicated in
patients with depression, anxiety
and psychiatric disorders10
Is there a family history
of epilepsy?
Use of chloroquine and mefloquine
contraindicated10,12,13
Is there a history of previous
travel, use of antimalarials or
history of allergy to any
medications?
Note any previous history of allergies
or preference of one antimalarial
over another
Male No
Yes
No
No
No
Yes
Yes
Yes
Yes
of adverse effects when drugs are used as
antimalarials, since many are also used for
other conditions, often at higher doses and
for longer periods of time.20 This is further
compounded by the fact that increasing
parasite resistance is leading to the use of
newer drugs where there is less experience
with respect to adverse effects.
Long-term travellers (>6 months) may
pose a particular challenge since most
chemoprophylactic agents are only licensed
for a limited period. The following options
may be considered: switching from one drug
to another when the limit is reached; using
proguanil with chloroquine despite the fact
that resistance has been reported (may be
used for periods up to 5 years14); not using
chemoprophylaxis and seeking advice if a
malaria attack occurs, or continuing beyond
the licensed duration of the drug. The latter
is considered the more suitable since most
adverse effects occur at the start of
treatment rather than later.20
Diagnosing breakthrough
malaria swiftly and
obtaining proper treatment
Emergency standby treatment is
recommended for travellers taking
prophylaxis and, who are unlikely to be
within 24 hours reach of a doctor. The drug
given should be different to the
chemoprophylactic drug. Atovaquone/
proguanil or co-artemether (artemisinin with
lumefantrine) are recommended as stand-by
treatment, with quinine recommended only
in pregnancy.20 Travellers should be advised
to seek medical advice if they develop a
febrile illness within 3 months of return.
Conclusion
Since the discovery of the malaria
parasites in human blood by Charles Louis
Alphonse Laveran in 1880 and the
description of the complete life cycle in
birds by Ronald Ross in 1898, there have
been numerous breakthroughs in elucidating
the pathogenesis as well as the treatment of
this deadly disease.30,31 No sooner had any
hopes of malaria eradication been put
forward that the first drawbacks were seen.
Resistance to the most common
antimalarials has necessitated looking at
other alternatives, including combination
treatment, in order to curb this disease.18
Still, statistics about malaria infections
worldwide are far from comforting. The
“prevention is better than cure” adage
definitely applies and in fact, advice and
appropriate chemoprophylaxis to people
travelling to malarious areas is as important
as diagnosing and treating malaria cases.
Table 2 lists sources of regularly updated
information on the choice of appropriate
antimalarials.
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